Genesis Biopharma appoints new ceo and cfo
Anthony Cataldo and Michael Handelman also join board of directors
In addition Genesis Biopharma has appointed Michael Handelman as chief financial officer, treasurer and secretary, succeeding Richard McKilligan.
Cataldo and Handelman have joined the company's Board, while Brooke, McKilligan and Mark Ahn have resigned as members.
‘I'm looking forward to working with the Genesis Biopharma board to further the progress of our important cancer technology, and to develop new strategic opportunities to build shareholder value,’ said Cataldo.
‘Genesis Biopharma's targeted anti-CD55 monoclonal antibody technology has widespread clinical utility, as it neutralises a key cancer defence mechanism that is over-expressed in more than 80% of tumours. It could provide a safe alternative to toxic chemotherapy regimens, and has the potential to expand and improve the clinical utility of already approved antibody therapies as well as some novel agents in development.’
Cataldo was formerly chairman, chief executive and a director of Oxis International. Prior to this he was non-executive co-chairman of the Board of MultiCell Technologies.
Handelman was chief financial officer of Oxis International. Prior to this he was cfo and coo of TechnoConcepts.
You may also like
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development
FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design
The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Research & Development
Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive
Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
Research & Development
Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic
Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
Research & Development
Early stage clinical trials highlight the convergence of novel therapeutics and enabling technologies
Early stage clinical development is increasingly being shaped by advances in drug discovery and the technologies and manufacturing strategies that enable the safe, precise and scalable delivery of new therapies
Research & Development
Breast cancer is the world’s most studied disease for fifth consecutive year according to analysis from Phesi
The US led global clinical trial activity in 2025 and across all top five indications, with China recording the fastest growth in the number of recruiting clinical trial sites
Research & Development
One in ten Britons are using or interested in using GLP-1s for weight loss, according to new research
GLP-1 use and interest was more prevalent among women, as well as those who reported difficulties with their finances or who had experienced psychological distress within the previous month